@DrRaniKhatib But 4 in 5 do feel that they participated. Would be interesting to look at when DOACs were initiated and who by so we can ensure everyone can have valuable conversations involving shared decision making.
.@kaj33 is one of many living with #AFib, a common type of irregular heartbeat. He teamed up with BMS & Pfizer to encourage those with symptoms that could indicate AFib or another condition to speak with a healthcare professional. Learn more: https://t.co/GOeD52Ve1I #WTDay23
@DrRaniKhatib Interested to know your thoughts on whether we should be saying for life or saying long term while the benefits outweigh the risks? The wording we use is so important.
It’s arrived.
#TikTokXmas#DancingDrBob
Text XMASTIKTOK to 70085 to donate £5 to CCLG. Texts will cost the donation amount plus one standard network rate message.
Alternatively donate at this link
https://t.co/r6DHk454sT
@KindlyLoudly
OSCAR-US-H2H observational study comparing rivaroxaban to apixaban for the management of cancer-associated-thrombosis showed that both are effective and safe. No statistical difference in any outcomes was observed after 3 or 6 months of follow up. #ASH22
Educational session in selected populations. Good talk on anticoagulation in women #ASH22. DO NOT STOP ORAL CONTRACEPTIVES AT TIME of START ANTICOAGULATION FOR VTE.
Calling my researcher friends and colleagues! A great opportunity has come up at Leeds Teaching Hospitals - An Embedded Researcher Role! Interested? 👀Read on! 👉 https://t.co/V9YAu1x6hq
Authoritative guidance from the American Heart Association on the diagnosis and management of left ventricular thrombus. Treatment with DOAC is a reasonable option. https://t.co/SvEDAX4nmm #thrombosis#DOAC
Please Share! A new WTD survey for patients with cancer aims to assess patients' knowledge & satisfaction about the information received by healthcare providers on the potential risks of cancer-associated blood clots & use of blood thinners.
https://t.co/Fs1nGI0W2n
#WTDay22